Pursuant to regulation 30 of SEBI(LODR) Regulations, 2015, we are enclosing a press release for the decision of the Company to form a WOS in Singapore for expansion in South-East Asia.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aayush Wellness Limited has received board approval to set up a wholly owned subsidiary in Singapore with an initial capital of SGD 10,000. The new entity will serve as a launchpad for the company's nutraceutical and healthcare products in Southeast Asian markets including Malaysia, Indonesia, Thailand, and Vietnam. The company highlighted that the Southeast Asian nutraceutical market is projected to reach USD 15.1 billion by 2028 at a 7.5% CAGR, with Singapore's own nutraceutical sector valued at over USD 1.3 billion. Focus areas include localizing products, building e-commerce distribution, forging regional partnerships, and setting up an R&D hub. This is part of Aayush Wellness's broader global growth strategy as an ISO-certified integrated healthcare company established in 1989.
The move signals international expansion ambitions, but the initial capital of SGD 10,000 (roughly ₹6 lakh) is very small, suggesting this is an exploratory step rather than a large-scale investment. Shareholders should watch for further capital commitments and actual revenue traction from Southeast Asia before viewing this as a material growth driver.